{"id":614609,"title":"Regulating autologous stem cell products prepared at point-of-care: Summary report - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-03-02","captureTimestamp":"2026-03-02T02:55:26.699000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/biologics-radiopharmaceuticals-genetic-therapies/regulating-autologous-stem-cell-products-prepared-point-care-summary.html","snippet":"Regulating autologous stem cell products prepared at point-of-care: Summary report On this page About the virtual workshop Opening remarks Clinical trials framework Current and planned regulations for new drugs Clinical trial sponsor perspective FDA perspective Alberta's…","rawSnapshotUrl":"/api/snapshots/raw/614609","browseUrl":"https://replay.healtharchive.ca/job-6/20260302025526/https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/biologics-radiopharmaceuticals-genetic-therapies/regulating-autologous-stem-cell-products-prepared-point-care-summary.html#ha_snapshot=614609","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}